Services of MTRC

Our goal at MTRC is to inform the decision-making of our clients and to support their market access activities. Below is a snapshot of our planned activities for the next two weeks. This can help our existing and prospective clients understand the potential scope of our support better. From the week of August 11th, we plan to work on 16 projects. Review the complete list of planned activities in this post.

MTRC is pleased to present 2025 In-Vitro Diagnostic Tests Market Access Playbook - your annual, refresh‑and‑reuse roadmap to every EU reimbursement deadline.

MTRC has released a White Paper titled "Evidence Requirements for IVD Tests in NICE HealthTech Evaluations ". This white paper reviews five assessments of IVD diagnostic technologies conducted under NICE’s previous Diagnostics Assessment Programme (DAP) framework. While terminology and processes have evolved with the introduction of the HealthTech Evaluation Program, these case studies remain highly informative. They offer practical insights into NICE’s evidence expectations and common drivers of recommendation decisions, which continue to shape current evaluation approaches.

Our goal at MTRC is to inform the decision-making of our clients and to support their market access activities. Below is a snapshot of our planned activities for the next two weeks. This can help our existing and prospective clients to understand the potential scope of our support better. From the week of July 28th, we plan to work on 16 projects. Review the complete list of planned activities in this post.

MTRC has released a White Paper titled "Clinical evidence requirements for the “Orderly Introduction of Medical Technologies” process in Sweden". This report provides an opportunity to learn about the evidence requirements of Sweden's Dental and Pharmaceutical Benefits Agency (TLV) and the Medical Technology Product (MTP) Council in relation to the national process of Orderly Introduction of medical technologies. White Paper outlines the key points and recommendations for the MedTech industry informed by three HTA reports with positive recommendations.

MTRC has released a White Paper titled "Evidence requirements for AI-based technologies in Europe." This Paper reviews evidence requirements for AI-based technologies as identified in five recent European HTA assessments, including urgent-care fracture detection (NICE, UK), hyperacute stroke imaging (NICE, UK), colonoscopic polyp detection (Danish Health Technology Council), and breast cancer screening programs (OSTEBA in Spain and SBU in Sweden).

Our goal at MTRC is to inform the decision-making of our clients and to support their market access activities. Below is a snapshot of our planned activities for the next two weeks. This can help our existing and prospective clients to understand the potential scope of our support better. From the week of July 14th, we plan to work on 19 projects. Review the complete list of planned activities in this post.

MTRC is pleased to present the 2025 European MedTech Market Access Playbook - your annual, refresh‑and‑reuse roadmap to every EU reimbursement deadline.

MTRC is pleased to announce the release of its latest White Paper: “Case study: Market Size Analysis for Mechanical Intracranial Thrombectomy in Europe”. The report highlights the role of procedure and diagnosis coding data in evaluating market size and demonstrates the methodologies of how the administrative databases from multiple European countries – the French CCAM, German OPS and Spanish CIE-10-ES – can be used to quantify real-world procedure volumes, characterize types of devices used and with that potential reimbursement pathways for the new technology.

Driven by the substantial productivity growth and increase in the size of the team, MTRC now offers a flexible, three-tier system - Start-up, Basic, and Comprehensive, for health economic models to medical device, in-vitro diagnostic, and digital technology companies. With competitive entry-level pricing of just €13,500 and €21,500, now is the perfect time to equip your team with an impactful health economic argument to power your market access and commercial success across Europe and globally.

Driven by the substantial productivity growth and increase in the size of the team, MTRC now offers a flexible, three-tier system - Start-up, Basic, and Comprehensive, for creating value dossiers tailored to medical devices, IVD tests, and digital technologies. With competitive entry-level pricing of just €12,500 and €19,500, now is the perfect time to equip your team with an impactful dossier to power your market access and commercial success across Europe and globally.

Our goal at MTRC is to inform the decision-making of our clients and to support their market access activities. Below is a snapshot of our planned activities for the next two weeks. This can help our existing and prospective clients to understand the potential scope of our support better. From the week of June 30th, we plan to work on 15 projects. Review the complete list of planned activities in this post.